Premier Biomedical CEO Interviewed by The Wall Street Transcript
ST. PETERSBURG, Fla., April 30, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that President and Chief Executive Officer William Hartman was recently interviewed by The Wall Street Transcript (TWST), an independent investment publication of interviews with company CEOs, money managers, and Wall Street analysts. The Bill Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (212) 952-7433 or via The Wall Street Transcript Online (http://www.twst.com/report/1975).
In the interview, Mr. Hartman discusses Premier Biomedical's revolutionary approach to medical treatment research and development. Employing the Felder Doctrine™ developed by company co-founder Dr. Mitchell Felder, Premier Biomedical physically removes the pathophysiologic basis of a disease by processing the body fluids, such as blood for blood-borne diseases and cerebral spinal fluid for neurologic-based diseases. Premier Biomedical has been successful in killing a cancer tumor in a test tube by simply eliminating the molecular compounds determined to be important in the growth factor of cancer. The company's procedure takes only about 10 minutes, and within 24 hours the cancer tumor dies. The process is currently being tested in mice.
In addition to the company's technology, Mr. Hartman spoke about Premier's collaborative agreements with the University of Texas at El Paso (UTEP) and the William Beaumont Army Medical Center (WBAMC). He noted that through the scientific progress being made in cooperation with UTEP and WBAMC, the company's goal is to complete research and development and bring to market potential medications/procedures for its targeted diseases.
Commenting on the interview with TWST, Mr. Hartman stated, "Exciting new technology developments are happening at Premier Biomedical and we are pleased to share our story with the prestigious readers of The Wall Street Transcript. As a public company, we are becoming more active in our direct communications with the investment community through our own announcements and through important venues like TWST."
For a copy of the Biotechnology and Pharmaceuticals issue or for information on subscribing to The Wall Street Transcript, call (212) 952-7433 or visit The Wall Street Transcript Online (http://www.twst.com/report/1975).
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." www.premierbiomedicalinc.com
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
William A. Hartman, CEO
SOURCE Premier Biomedical, Inc.